title: Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes.
abstract: BACKGROUND
  Gastric cancer (GC) is one of the most common cancers in China. Adjuvant chemotherapy (AC) is a routine auxiliary treatment for GC recommended by the guidelines issued in 2011 by the Ministry of Health of the People's Republic of China, but the relevant credible consequences in China have been insufficient because of China's late start and ethical concerns.
  
  
  METHODS
  A series of databases, including Cochrane Library, MEDLINE, EMBASE, the Chinese database of the National Knowledge Infrastructure and the VIP database, were searched by 2 reviewers independently for studies investigating AC for GC through March 2012. The retrieved literature was screened according to the eligibility criteria.
  
  
  RESULTS
  A total of 35 randomized control trials (RCTs) were subjected to the final analysis, including 4,043 patients in treatment group and 3,884 in the control group, as well as 4 clinical-control trials (CCTs), which accessed the final analysis with 238 and 252 patients, respectively. AC reduced the risk of death as a protective treatment with statistical significance (HR=0.91, 95%CI: [0.85, 0.97], P=0.002), and it seemed more effective for Asian than non-Asian patients. The effects of AC were not influenced by the starting time (P>0.05). D2 lymphadenectomy-based chemotherapy was effective (HR=0.89, 95%CI: [0.80, 0.99], P=0.04). Oral S-1 40 mg/m2 after D2 lymphadenectomy might be a better choice for Asians with advanced GC and might result in a greater reduction of adverse events than in non-Asian patients. GRADE quality assessment determined that the strength of the evidence from foreign studies from Europe, the United States and Asian countries other than China was high, while it was moderate for Chinese studies.
  
  
  CONCLUSIONS
  AC was effective or even curative in Chinese patients in general, although it is still necessary to optimize a targeted AC scheme for Chinese patients with GC.
authors.affiliation: Department of Oncology, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center, China.
authors.forename: Wen-Tao
authors.initials: WT
authors.lastname: Shi
authors.forename: Lei
authors.initials: L
authors.lastname: Wei
authors.forename: Jin
authors.initials: J
authors.lastname: Xiang
authors.forename: Ke
authors.initials: K
authors.lastname: Su
authors.forename: Qiong
authors.initials: Q
authors.lastname: Ding
authors.forename: Meng-Jie
authors.initials: MJ
authors.lastname: Tang
authors.forename: Ji-Qiang
authors.initials: JQ
authors.lastname: Li
authors.forename: Yi
authors.initials: Y
authors.lastname: Guo
authors.forename: Pu
authors.initials: P
authors.lastname: Wang
authors.forename: Jing-Wei
authors.initials: JW
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044466:Asian People; D017024:Chemotherapy, Adjuvant; D006801:Humans; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012196:Review Literature as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents